Clinical Trials Logo

Mouth Diseases clinical trials

View clinical trials related to Mouth Diseases.

Filter by:

NCT ID: NCT03909074 Completed - Clinical trials for Hand, Foot and Mouth Disease

Clinical Trial of Enterovirus 71(EV71) Inactivated Vaccine in Children Aged 36-71 Months

Start date: March 10, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the non-inferiority of experimental EV71 vaccine compared to the control EV71 vaccine in children aged 36-71 months, to evaluate the non-inferiority of EV71 vaccine used in children aged 36-71 months compared to 6-35 months. The experimental vaccine was manufactured by Sinovac Biotech Co., Ltd, and the control vaccine was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.

NCT ID: NCT03903926 Completed - Clinical trials for Hand, Foot and Mouth Disease

Efficacy Trial of a Commercial EV71 Vaccine

Start date: March 26, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this post-marketing study is to evaluate the efficacy, immunogenicity, and safety of the EV71 vaccine post marketing, and explore the protective levels of various enterovirus neutralizing antibodies

NCT ID: NCT03893747 Completed - Clinical trials for Hand, Foot and Mouth Disease

Immunity and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China

Start date: April 1, 2019
Phase: Phase 4
Study type: Interventional

This study evaluates three batches consistency, immunity duration and safety of inactivated Enterovirus 71(EV-A71) vaccine(vero cell) post-marketing among children aged 6-35months in China.3000 subjects will be recruited in this study, of who 1500 subjects will be randomly assigned in a ratio of 1:1:1 to receive one of the three batches of EV-A71 vaccines manufactured by 40L capacity reactor, other 1500 subjects will be randomly assigned in a ratio of 1:1:1 to receive one of the three batches of EV-A71 vaccines manufactured by 150L capacity reactor. Vaccine wil be administrated according to a two doses of schedule given at day 0 and 28. Sample will be collected at day 0, day 56 and at month 13 after vaccinaiton.

NCT ID: NCT03873740 Completed - Clinical trials for Hand, Foot and Mouth Disease

Immunogenicity and Safety of Two Different Commercial EV71 Vaccines

Start date: November 6, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and safety of sequential vaccination of two EV71 inactived vaccines in healthy infants aged 6-35 months.

NCT ID: NCT03855397 Completed - Oral Cavity Disease Clinical Trials

Pain and Safety of Microneedles in Oral Cavity

Start date: January 16, 2018
Phase: N/A
Study type: Interventional

A randomized, crossover, double-blind, placebo-controlled, one-session clinical trial with 30 male volunteers was performed to access pain and safety of microneedle topical application in different regions of the oral cavity.

NCT ID: NCT03723174 Completed - Oral Disease Clinical Trials

Impact of an Educational Program on Gingival Status and Oral Health Related Quality of Life

Start date: November 1, 2020
Phase:
Study type: Observational [Patient Registry]

This research targets the evaluation of the impact of oral health educational programs on the gingival status and oral health related quality of life in early adolescence of the Egyptian population. Each participant will benefit from the education of the proper oral hygiene practices under the supervision and follow up of the investigator in addition to the potential improvement of his/ her oral health related quality of life.

NCT ID: NCT03582761 Completed - Clinical trials for Hand, Foot and Mouth Disease

Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71

Start date: May 1, 2019
Phase: Phase 4
Study type: Interventional

This study is a multicenter, case-control phase IV clinical trial to evaluate the effectiveness of the EV71 vaccine. About 40000 children in the town aged 6-35 months will be recruited and vaccinated with EV71 vaccines, which account for 20-40% of the children aged 6-35 months in the areas. The subjects will be vaccinated with EV71 vaccine at day 0 and day 28. Other children of appropriate age in the town will choose voluntarily whether or not to be vaccinated with EV71 vaccine. All children's vaccination of EV71 vaccines will be recorded in the study areas and the coverage rate of EV71 vaccine in the town will be calculated. The vaccination is expected to complete before the epidemic peak of HFMD. Surveillance of HFMD cases caused by EV71 will be conducted in hospitals of the study areas for 10-12 months, which cover a whole HFMD epidemic period. Throat and anal swabs will be collected from children with a clinically diagnosed HFMD for typing of human enteroviruses tested by PCR. The HFMD cases with EV71 positive will be recruited as cases, while those with EV71 negative will be recruited as test-negative controls. Besides, for each EV71-associated HFMD cases, the investigators will select 4 community controls mateced with each case for age, sex and residence.

NCT ID: NCT03438045 Completed - Dental Caries Clinical Trials

Implementing a Participatory, Multi-level Intervention to Improve Asian American Health Study

Start date: May 9, 2018
Phase: N/A
Study type: Interventional

This feasibility and acceptability study will be conducted at 3 community outreach centers serving an urban, low-income Chinese population. The study will evaluate the feasibility and acceptability of implementing a partnered intervention to improve the oral and general health of low-income, urban Chinese American adults and of using remote data entry into an electronic health record (EHR). The research staff will survey a sample of Chinese American patients screened at each center about their satisfaction with the partnered intervention and about their oral health behaviors. An additional sample selected from providers [dentists and community health workers (CHW)], research staff, New York University (NYU) administrators, site directors, and community advisory board (CAB) members will participate in structured interviews about the partnered intervention. The remote EHR evaluation will include group adaptation sessions and workflow analyses via multiple recorded sessions with research staff, NYU administrators, outreach site directors, and providers (dentists and CHWs). The study will also model knowledge held by these non-patient participants (including CAB members) to evaluate and enhance the partnered intervention during and/or after the feasibility and acceptability study for use in future implementations.

NCT ID: NCT03429829 Completed - Dental Caries Clinical Trials

Fluoride Varnish Community Trial

Start date: February 12, 2018
Phase: N/A
Study type: Interventional

This cluster-randomized controlled community trial aimed to assess the efficacy and costs of fluoride varnish application for caries prevention in a high-risk population in South Africa.

NCT ID: NCT03281174 Completed - Clinical trials for Hand, Foot and Mouth Disease

Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine

Start date: May 20, 2017
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the 5-year Immune Persistence of Inactivated Enterovirus Type 71 (EV71) Vaccine manufactured by Sinovac (Beijing) Biotech Co., Ltd.